Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: A translational toxicokinetic/toxicodynamic analysis

Toxicological Sciences

Volumn 130, Issue 1, 2012, Pages 205-213

  Wong, Harvey ^a   Budha, Nageshwar R ^a   West, Kristina ^a   Blackwood, Elizabeth ^a   Ware, Joseph A ^a   Yu, Ron ^a   Darbonne, Walter C ^a   Gould, Stephen E ^a   Steigerwalt, Ronald ^a   Erickson, Rebecca ^a   Hop, Cornelis E A C ^a   LoRusso, Patricia ^b   Gail Eckhardt, S ^c   Wagner, Andrew ^d   Chan, Iris T ^a   Mamounas, Michael ^a   Flygare, John A ^a   Fairbrother, Wayne J ^a  

^a GENENTECH INC   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

IAP; Pharmacokinetic pharmacodynamic; PK PD; TK TD; Toxicodynamics; Toxicokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CYTOKINE; GDC 0152; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG STRUCTURE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; SIMULATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

ANIMALS; AREA UNDER CURVE; CASPASE INHIBITORS; CYCLOHEXANES; CYTOKINES; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 84867816814     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs235     Document Type: Article

References (28)

1. Aydinli, M., and Bayraktar, Y. (2007). Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J. Gastroenterol. 13, 2693-2696.
2. Bauer, R. J., and Guzy, S. (2004). Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/ pharmacodynamic (PK/PD) data. In Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis (D. Z. D'Argenio, Ed.), pp. 135-163. Kluwer, Boston, MA.
3. Brobmann, G. F., Ulano, H. B., Hinshaw, L. B., and Jacobson, E. D. (1970). Mesenteric vascular responses to endotoxin in the monkey and dog. Am. J. Physiol. 219, 1464-1467.
4. Cavanagh, D., Rao, P. S., Sutton, D. M., Bhagat, B. D., and Bachmann, F. (1970). Pathophysiology of endotoxin shock in the primate. Am. J. Obstet. Gynecol. 108, 705-722.
5. D'Argenio, D., and Schumitzky, A. (1997). ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software. Biomedical Simulations Resources, Los Angeles, CA.
6. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095.
7. DeGeorge, J. J., Ahn, C. H., Andrews, P. A., Brower, M. E., Giorgio, D. W., Goheer, M. A., Lee-Ham, D. Y., McGuinn, W. D., Schmidt, W., Sun, C. J., et al. (1998). Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol. 41, 173-185.
8. Dueber, E. C., Schoeffler, A. J., Lingel, A., Elliott, J. M., Fedorova, A. V., Giannetti, A. M., Zobel, K., Maurer, B., Varfolomeev, E., Wu, P., et al. (2011). Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376-380.
9. Erickson, R., Tarrant, J., Cain, G., Dybdal, N., Lewin-Koh, S. C., Wong, H., Blackwood, E., West, K., Almeida, D., Amemiya, K., et al. (2011). Toxicology profile of small-molecule IAP Antagonist GDC-0152 is associated to TNF-alpha pharmacology. American College of Toxicology Annual Meeting Abstract.
10. Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012). Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 55, 4101-4113.
11. Flygare, J. A., and Fairbrother, W. J. (2010). Small-molecule pan-IAP antagonists: A patent review. Expert Opin. Ther. Pat. 20, 251-267.
12. Graham, M. A., Mitsuuchi, Y., Burns, J., Chunduru, S., Benetatos, C., McKinlay, M., Weng, D., Wick, M. J., Tolcher, A. W., Papadopoulos, K., et al. (2011). Phase 1 PK/PD analysis of the Smac-mimetic TL32711 demonstrates potent and sustained cIAP1 suppression in patient PBMCs and tumor biopsies. AACR-NCI-EORTC International Conference Abstract, Nov 2011, San Francisco, CA.
13. Gilbaldi, M., and Perrier, D. (1982). Pharmacokinetics, 2nd ed. Marcel Dekker Inc., New York, NY.
14. Hamano, T., Tong, V., Mutai, M., Hayashi, M., and Tanaka, E. (2002). Kupffer cell-mediated cytotoxicity induced by lipopolysaccharide 0111:B4 is greater in dogs than in rats and monkeys. J. Toxicol. Sci. 27, 1-9.
15. ICH. (2010). Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals.
16. Infante, J. R., Dees, E. C., Burris, H. A., Zawei, L., Sager, J. A., Stevenson, C., Clarke, K., Dhuria, S., Porter, D., Sen, S. K., et al. (2010). A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer. AACR 101st Annual Meeting 2010 Abstract, April 2010, Washington, DC.
17. Legare, D. J., and Lautt, W. W. (1987). Hepatic venous resistance site in the dog: Localization and validation of intrahepatic pressure measurements. Can. J. Physiol. Pharmacol. 65, 352-359.
18. Ndubaku, C., Varfolomeev, E., Wang, L., Zobel, K., Lau, K., Elliott, L. O., Maurer, B., Fedorova, A. V., Dynek, J. N., Koehler, M., et al. (2009). Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 4, 557-566.
19. Roberts, N. J., Zhou, S., Diaz, L. A., Jr, and Holdhoff, M. (2011). Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2, 739-751.
20. Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., et al. (2011). Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J. Clin. Oncol. 29, 3008 (Abstract).
21. Varfolomeev, E., Alicke, B., Elliott, J. M., Zobel, K., West, K., Wong, H., Scheer, J. M., Ashkenazi, A., Gould, S. E., Fairbrother, W. J., et al. (2009). X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J. Biol. Chem. 284, 34553-34560.
22. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681.
23. Varfolomeev, E., and Vucic, D. (2011). Inhibitor of apoptosis proteins: Fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 7, 633-648.
24. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., et al. (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693.
25. Vucic, D., and Fairbrother, W. J. (2007). The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 13, 5995-6000.
26. Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F. P., Tibbitts, J., Friedman, L. S., Hop, C. E., et al. (2012a). Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 18, 3846-3855.
27. Wong, H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J. F., Yu, P., Li, C., Del Rosario, G., Choo, E. F., et al. (2012b). Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: An analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 18, 3090-3099.
28. Yadav, A., Saini, V., and Arora, S. (2010). MCP-1: Chemoattractant with a role beyond immunity: A review. Clin. Chim. Acta 411, 1570-1579.